NCT05515042View on ClinicalTrials.gov

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

694

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
COVID-19
Interventions
DRUG

Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)

As included in arm/group descriptions

Trial Locations (5)

1632

The Aurum Institute: Tembisa Clinical Research Centre, Clinic 4, Tembisa

The Aurum Institute: Tembisa Clinical Research Centre, Tembisa

2571

The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp

0087

The Aurum Institute: Pretoria Clinical Research Centre, Pretoria

0299

The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg

All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

The Aurum Institute NPC

OTHER